{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T04:07:15Z","timestamp":1794283635730,"version":"4.9.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003715","name":"Korea Research Institute of Bioscience and Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003715","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["RS-2024-00332401"],"award-info":[{"award-number":["RS-2024-00332401"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jchromb.2025.124836","type":"journal-article","created":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:35:00Z","timestamp":1761496500000},"page":"124836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Development and validation of an LC-MS\/MS method for Tirzepatide, a dual GIP\/GLP-1 receptor agonist, in rat plasma for application to a pharmacokinetic study"],"prefix":"10.1016","volume":"1268","author":[{"given":"Hae-In","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Cheol","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Woo","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da Hae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyong-Cheol","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Jee","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeong-Ryoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2025.124836_bb0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.jchromb.2025.124836_bb0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7570\/jomes22067","article-title":"Efficacy and safety of tirzepatide in type 2 diabetes and obesity management","volume":"32","author":"Sinha","year":"2023","journal-title":"J. Obesity & Metabolic Syndrome"},{"key":"10.1016\/j.jchromb.2025.124836_bb0015","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jchromb.2025.124836_bb0020","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s40265-022-01746-8","article-title":"Tirzepatide: first approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jchromb.2025.124836_bb0025","article-title":"FDA approves new obesity drug from Eli Lilly named Zepbound","author":"Gilbert","year":"2023","journal-title":"Wash. Post"},{"key":"10.1016\/j.jchromb.2025.124836_bb0030","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"New England J. Medicine"},{"key":"10.1016\/j.jchromb.2025.124836_bb0035","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"New England J. Medicine"},{"key":"10.1016\/j.jchromb.2025.124836_bb0040","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2025.124836_bb0045","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jchromb.2025.124836_bb0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.27258","article-title":"Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes","volume":"7","author":"Chuang","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jchromb.2025.124836_bb0055","doi-asserted-by":"crossref","first-page":"100023","DOI":"10.53941\/ijddp.2024.100023","article-title":"Tirzepatide in treating metabolic disorders","volume":"3","author":"Wei","year":"2024","journal-title":"Int. J. Drug Discov. Pharmacol."},{"key":"10.1016\/j.jchromb.2025.124836_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2024.124159","article-title":"White analytical insight for sensitive fluorescent determination of semaglutide and tirzepatide in pharmaceuticals and biological matrices","volume":"313","author":"Mansour","year":"2024","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.jchromb.2025.124836_bb0065","series-title":"Quantification of Glucagon-like Peptide-1 Agonist Tirzepatide Using an Agilent 6495D Triple Quadrupole LC\/MS System","author":"Suresh Babu","year":"2024"},{"key":"10.1016\/j.jchromb.2025.124836_bb0070","series-title":"Determination of Semaglutide and Tirzepatide in Plasma, TN-1358","author":"Wang","year":"2024"},{"key":"10.1016\/j.jchromb.2025.124836_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106895","article-title":"Absorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys","volume":"202","author":"Martin","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jchromb.2025.124836_bb0080","series-title":"Clinical Pharmacology Review of Tirzepatide (Zepbound) \u2013 NDA 217806, Clinical Pharmacology Review","author":"Kronfol","year":"2023"},{"key":"10.1016\/j.jchromb.2025.124836_bb0085","series-title":"U. FDA, Bioanalytical Method Validation Guidance for Industry, US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and","year":"2018"},{"key":"10.1016\/j.jchromb.2025.124836_bb0090","series-title":"ICH, Bioanalytical Method Validation and Study Sample Analysis M10, ICH HARMONISED GUIDELINE","year":"2022"},{"key":"10.1016\/j.jchromb.2025.124836_bb0095","series-title":"Shimadzu Analytical (India)","article-title":"Simple, Sensitive and rapid quantification of Teriparatide in human plasma by LCMS-8060","author":"Gaikwad","year":"2023"},{"key":"10.1016\/j.jchromb.2025.124836_bb0100","series-title":"U.S. Food and Drug Administration","article-title":"Clinical pharmacology and biopharmaceutics review(s): Tirzepatide (Mounjaro)","author":"C.f.D.E. Fda, Research","year":"2022"},{"key":"10.1016\/j.jchromb.2025.124836_bb0105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/dom.14843","article-title":"Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents","volume":"25","author":"Geisler","year":"2023","journal-title":"Diabetes Obes. Metab."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225003903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225003903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:27:04Z","timestamp":1781195224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023225003903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":21,"alternative-id":["S1570023225003903"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124836","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of an LC-MS\/MS method for Tirzepatide, a dual GIP\/GLP-1 receptor agonist, in rat plasma for application to a pharmacokinetic study","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124836","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"124836"}}